newsfilter
← Latest News
GlobeNewswire·

AGTC Announces Robust Improvements in Visual Sensitivity in Adult and Pediatric Patients, and Plans to Continue Clinical Development of AGTC-401 in Patients with CNGB3 Achromatopsia

AGTC-401 demonstrated a favorable safety profile through second-highest dose (1.1E+12 vg/mL) in ACHMB3 pediatric patients At the dose of 1.1E+12 vg/mL greater than 50% of the combined adults and children that received AGTC-401 were responders based on